Precision Drilling
PDS
Lantheus
LNTH
Dorian LPG
LPG
Collegium Pharmaceutical
COLL
Halozyme Therapeutics
HALO
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 9.18%18.56B | 11.81%17.87B | 14.08%17.22B | 21.98%66.5B | 15.46%18.42B | 22.92%17B | 20.26%15.98B | 31.92%15.1B | 30.13%54.52B | 38.06%15.95B |
Operating revenue | 9.18%18.56B | 11.81%17.87B | 13.64%18.83B | 21.95%72.79B | 15.55%20.16B | 22.92%17B | 20.26%15.98B | 44.78%16.57B | 30.71%59.68B | 13.90%17.45B |
Excise taxes | ---- | ---- | 9.04%1.6B | 21.36%6.14B | 16.08%1.7B | ---- | ---- | --1.47B | 37.10%5.06B | --1.46B |
Cost of revenue | 8.88%15.51B | 11.20%14.92B | 13.83%14.42B | 22.22%55.68B | 16.14%15.35B | 23.04%14.25B | 20.40%13.42B | 31.73%12.67B | 31.09%45.56B | 38.14%13.22B |
Gross profit | 10.74%3.05B | 14.98%2.95B | 15.40%2.8B | 20.73%10.82B | 12.20%3.07B | 22.32%2.76B | 19.53%2.56B | 32.97%2.43B | 25.44%8.96B | 37.66%2.74B |
Operating expense | 12.33%2.11B | 13.49%2.09B | 9.59%2B | 25.49%7.64B | 9.37%2.04B | 23.65%1.88B | 27.18%1.84B | 39.42%1.83B | 33.44%6.09B | 50.32%1.87B |
Selling and administrative expenses | 9.64%1.73B | 14.73%1.7B | 7.21%1.62B | 20.83%6.24B | 4.70%1.67B | 23.88%1.58B | 23.44%1.48B | 37.83%1.51B | 31.72%5.17B | 45.84%1.6B |
-Selling and marketing expense | 7.89%1.48B | 15.43%1.5B | 8.42%1.42B | 23.57%5.41B | 3.76%1.43B | 28.81%1.37B | 29.52%1.3B | 40.58%1.31B | 31.34%4.38B | 43.51%1.38B |
-General and administrative expense | 21.05%253M | 9.60%194M | -0.49%205M | 5.59%831M | 10.70%238M | -0.95%209M | -8.29%177M | 22.62%206M | 33.84%787M | 62.88%215M |
Depreciation amortization depletion | 5.68%391M | 12.90%385M | 21.09%379M | 51.69%1.39B | 37.04%370M | 59.48%370M | 60.09%341M | 53.43%313M | 44.04%919M | 52.54%270M |
-Depreciation and amortization | 5.68%391M | 12.90%385M | 21.09%379M | 51.69%1.39B | 37.04%370M | 59.48%370M | 60.09%341M | 53.43%313M | 44.04%919M | 52.54%270M |
Other operating expenses | 90.77%-6M | -77.78%4M | ---- | ---- | ---- | -482.35%-65M | -47.06%18M | ---- | ---- | ---- |
Operating profit | 7.31%939M | 18.76%861M | 33.00%802M | 10.67%3.19B | 18.25%1.03B | 19.54%875M | 3.72%725M | 16.63%603M | 11.33%2.88B | 16.60%871M |
Net non-operating interest income expense | -3.26%-761M | -14.49%-719M | -8.17%-702M | -80.26%-2.73B | -64.04%-730M | -67.50%-737M | -91.46%-628M | -114.90%-649M | -107.53%-1.52B | -55.05%-445M |
Non-operating interest income | -8.43%76M | -8.47%54M | -62.79%16M | -19.08%123M | -54.55%20M | 18.57%83M | -23.38%59M | -38.57%43M | 74.71%152M | 183.02%44M |
Non-operating interest expense | 2.07%837M | 12.52%773M | 17.22%701M | 86.41%2.62B | 46.42%716M | 60.78%820M | 69.63%687M | 60.75%598M | 68.26%1.41B | 94.05%489M |
Total other finance cost | ---- | ---- | -81.91%17M | -10.31%235M | --34M | ---- | ---- | --94M | 1,555.56%262M | --0 |
Other net income (expense) | 41.67%17M | 33.33%16M | -231.43%-46M | 457.14%100M | 300.00%6M | -25.00%12M | 20.00%12M | 337.50%35M | -366.67%-28M | 93.62%-3M |
Gain on sale of security | ---- | ---- | -405.26%-58M | ---- | ---- | ---- | ---- | --19M | ---- | ---- |
Earnings from equity interest | 41.67%17M | 33.33%16M | 33.33%16M | 15.91%51M | 50.00%15M | -25.00%12M | 20.00%12M | 50.00%12M | -6.38%44M | 66.67%10M |
Special income (charges) | ---- | ---- | -200.00%-4M | 156.98%49M | 88.89%-3M | ---- | ---- | --4M | -62.26%-86M | ---27M |
-Less:Restructuring and merger&acquisition | ---- | ---- | --0 | -84.85%5M | -87.50%1M | ---- | ---- | --2M | -55.41%33M | --8M |
-Less:Other special charges | ---- | ---- | ---- | -94.74%1M | ---- | ---- | ---- | ---- | 311.11%19M | --17M |
-Gain on sale of property,plant,equipment | ---- | ---- | -166.67%-4M | 261.76%55M | 50.00%-1M | ---- | ---- | --6M | -383.33%-34M | ---2M |
Other non- operating income (expenses) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --14M | ---- |
Income before tax | 30.00%195M | 44.95%158M | 590.91%54M | -58.50%554M | -27.66%306M | -51.30%150M | -71.39%109M | -104.93%-11M | -27.80%1.34B | 2.42%423M |
Income tax | 211.43%39M | 174.47%35M | 92.77%-6M | -235.65%-156M | -47.06%9M | -229.63%-35M | -175.81%-47M | -1,022.22%-83M | -51.88%115M | 114.91%17M |
Net income | -15.68%156M | -21.15%123M | -16.67%60M | -41.80%710M | -26.85%297M | -34.16%185M | -51.10%156M | -66.36%72M | -24.22%1.22B | -22.96%406M |
Net income continuous Operations | -15.68%156M | -21.15%123M | -16.67%60M | -41.80%710M | -26.85%297M | -34.16%185M | -51.10%156M | -66.36%72M | -24.22%1.22B | -22.96%406M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -15.68%156M | -21.15%123M | -16.67%60M | -41.80%710M | -26.85%297M | -34.16%185M | -51.10%156M | -66.36%72M | -24.22%1.22B | -22.96%406M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -15.68%156M | -21.15%123M | -16.67%60M | -41.80%710M | -26.85%297M | -34.16%185M | -51.10%156M | -66.36%72M | -24.22%1.22B | -22.96%406M |
Basic earnings per share | -15.69%0.5796 | -21.70%0.4516 | -16.03%0.2238 | -41.95%2.6279 | -27.10%1.0969 | -34.18%0.6875 | -51.31%0.5768 | -66.41%0.2665 | -24.43%4.5266 | -23.10%1.5046 |
Diluted earnings per share | -15.65%0.5771 | -21.62%0.4503 | -15.98%0.2233 | -41.86%2.6209 | -27.19%1.0956 | -34.18%0.6841 | -51.24%0.5745 | -66.26%0.2657 | -24.14%4.5079 | -23.10%1.5046 |
Dividend per share | 0 | 0 | 0 | -66.53%0.261 | 0 | 0 | -55.82%0.261 | 0 | 34.97%0.7798 | -22.44%0.189 |
Currency Unit | BRL | BRL | BRL | BRL | BRL | BRL | BRL | BRL | BRL | BRL |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |